Roche Pharmaceutical Development and Sales Overview

Evrysdi Global sales CHFbn CER growth Regional sales +101% CER growth 0.9 US +24% 0.8 0.7 Europe +335% 0.6 0.5 0.4 0.3 Japan >500% International +100% 0.2 0.1 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 793m • US: Strong growth driven by switch and treatment-naïve patients; market share increasing >20% • EU: Excellent growth driven by Germany and launches in key markets UK, Italy and France . International: Strong growth in all regions CER=Constant Exchange Rates Roche 164

View entire presentation